[
    "{\"step_by_step_thinking\": \"Cabozantinib is a tyrosine kinase inhibitor that has been approved for the treatment of advanced hepatocellular carcinoma (HCC) in patients who have previously received sorafenib. It works by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis. Several clinical trials have shown that cabozantinib can improve overall survival and progression-free survival in patients with advanced HCC. Therefore, the answer is yes.\", \"answer_choice\": \"A\"}"
]